Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

Exclusion Criteria

• •Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease
• •Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study
• •Hematologic disease
• •History of migraine headaches
• •History of encephalitis
• •Alcohol or drug abuse within 12 months prior to study entry
• •History of severe allergic reaction or anaphylaxis
• •Emergency room visit or hospitalization for severe asthma within 6 months prior to study entry
• •HIV-1 infected
• •Hepatitis C virus infected
• •Hepatitis B surface antigen positive
• •Known immunodeficiency syndrome
• •Use of corticosteroids or immunosuppressive drugs within 30 days of study entry. Participants who have used topical or nasal corticosteroids are not excluded.
• •Live vaccine within 4 weeks prior to study entry
• •Killed vaccine within 2 weeks prior to study entry
• •Blood products within 6 months prior to study entry
• •Participation in another investigational vaccine or drug trial within 60 days of starting this study, or while participating in this study
• •Previously received a licensed or experimental yellow fever, tick-borne encephalitis, or dengue vaccine
• •Surgical removal of spleen
• •History of West Nile encephalitis
• •History of dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus)
• •Other condition that, in the opinion of the investigator, would affect the participant's participation in the study
• •Pregnancy or breastfeeding